Neurosterix secured $105 million in a Series B to advance its schizophrenia pipeline, including Cobenfy-linked efforts. The funding round underscores continued investor appetite for CNS franchises that can differentiate on mechanism and address unmet need in difficult-to-treat psychiatric populations. The company positioned the financing to accelerate development of its lead schizophrenia candidate that targets one of Bristol Myers Squibb’s drug targets, with preclinical and early-stage data intended to de-risk differentiation and speed advancement toward pivotal testing. The round also highlights how schizophrenia drug development remains an active capital market area as clinical-stage timelines tighten.